The healthcare and medical device sector is witnessing a significant escalation in shareholder activism as Jana Partners, a prominent activist investment firm, has publicly called for a comprehensive restructuring of Cooper Companies (NYSE: COO). In a stinging rebuke of current management, Jana Partners has demanded the immediate removal of the Chief Executive Officer and the Board Chair, citing a series of operational missteps, poor capital allocation, and a failure to realize the value of the company’s core business segments. The move follows a period of stagnant growth for the California-based medical device manufacturer, which operates primarily through its CooperVision and CooperSurgical divisions.
The conflict between Jana Partners and Cooper Companies reached a boiling point following the release of the company’s third-quarter earnings report. While the company has long been a staple in the vision care and women’s health markets, recent financial performance and strategic reversals have frustrated investors. Jana Partners, which began building its stake in the company in late 2024, argues that the current leadership has failed to navigate the complexities of the post-pandemic market, particularly regarding inventory management and the execution of a long-promised strategic review of its surgical assets.
The Roots of the Dispute: A Failed Strategic Review
At the heart of the activist campaign is the "long, drawn-out strategic review" of the CooperSurgical segment. For several months, Cooper Companies’ CEO Al White had signaled to the market that the company was exploring a potential sale or spin-off of its surgical division. CooperSurgical, which specializes in fertility products, intrauterine devices (IUDs) like Paragard, and various surgical instruments, was viewed by many analysts as a high-value asset that could command a significant premium in a divestiture.
However, the company recently announced that it would be abandoning the sale process. White attributed the decision to a "temporary disconnect" between the intrinsic value of the surgical segment and the offers received from potential buyers. According to management, the proposals did not reflect the "full potential" of the business. Jana Partners has characterized this outcome as a failure of leadership, noting that the CEO had "repeatedly hyped" the sale process only to come up empty-handed. The activist firm suggests that the inability to secure a deal at an appropriate valuation points to a lack of credibility with strategic buyers and a failure to properly position the asset for market.
Operational Missteps in the Vision Segment
While the surgical segment faced strategic hurdles, the CooperVision division—the company’s primary revenue driver—has faced its own set of operational challenges. CooperVision is one of the "Big Four" global manufacturers of contact lenses, competing directly with industry giants like Alcon, Johnson & Johnson, and Bausch + Lomb. Despite a global increase in the prevalence of myopia and a steady demand for vision correction, Cooper’s revenue in this segment has remained largely flat year-over-year.
Jana Partners specifically targeted the company’s handling of "inflated" channel inventory. In the medical device and contact lens industry, channel inventory refers to the stock held by distributors and retailers. When a company "stuffs the channel"—pushing more product to distributors than there is end-user demand—it can artificially inflate short-term sales figures. However, this often leads to a subsequent "correction" where revenue drops as distributors work through their excess stock. Jana Partners alleged that Cooper’s management was forced to "slash" growth projections after realizing that inventory levels were unsustainable, a move the investor described as a "masterclass in how not to operate a company."
A Timeline of Escalation
The friction between Cooper Companies and Jana Partners did not emerge overnight. The following chronology outlines the progression of the current crisis:
- Late 2024: Jana Partners begins quietly accumulating a significant stake in Cooper Companies, identifying what it perceives as a widening "value gap" between the company’s share price and its underlying assets.
- Early 2025: CEO Al White begins publicly discussing a strategic review of the CooperSurgical segment, leading to market speculation of a multi-billion dollar divestiture.
- Mid-2025: Reports surface that several private equity firms and strategic healthcare companies have entered the bidding process for CooperSurgical. Cooper’s stock experiences volatility as investors weigh the likelihood of a sale.
- Third Quarter 2025: Cooper Companies releases its quarterly earnings, revealing flat growth in the vision segment and the official termination of the surgical segment sale. Management also discloses a significant downward revision in growth guidance due to inventory issues.
- Post-Earnings Announcement: Jana Partners releases a public statement condemning the company’s leadership and calling for the immediate replacement of the CEO and the Board Chair.
Critiques of Capital Allocation and Executive Compensation
A major point of contention for Jana Partners is the company’s recent share repurchase program. Capital allocation—how a company chooses to spend its cash—is a primary focus for activist investors. Jana noted that Cooper Companies "aggressively" repurchased its own stock shortly before releasing the negative news regarding the failed surgical sale and the inventory gluts.
From an activist’s perspective, repurchasing shares at a high price right before a stock-dropping announcement is a waste of corporate resources. Jana argues that this capital could have been better utilized for debt reduction, internal R&D, or returned to shareholders at a more opportune time. The firm contends that this sequence of events demonstrates a lack of foresight and a failure by the Board of Directors to oversee management’s financial decisions.
To address these issues, Jana is demanding a total overhaul of the company’s compensation metrics. The investor wants executive pay to be more closely tied to performance and accountability, rather than metrics that can be easily manipulated or that do not reflect long-term shareholder value. Furthermore, Jana has called for the engagement of an external performance improvement consultant to conduct a top-to-bottom audit of the company’s operations.
Industry Context: The Competitive Landscape
To understand the stakes of this battle, one must look at the broader medical device landscape. The contact lens market is currently undergoing a shift toward daily disposables and specialized lenses for myopia management, such as CooperVision’s MiSight. While these are high-margin products, the competition is fierce. Alcon and Johnson & Johnson have massive marketing budgets and deep-rooted relationships with eye care professionals.
In the surgical and fertility space, the market is similarly competitive but highly fragmented. The fertility (IVF) market, in particular, is seen as a high-growth sector due to shifting demographics and increasing access to reproductive technology. Jana Partners argues that CooperSurgical’s assets are highly attractive to "strategic buyers"—meaning other healthcare companies that could integrate Cooper’s products into their own portfolios to achieve synergies. The activist’s demand that Cooper re-evaluate the sale of its surgical assets suggests they believe a deal is still possible if handled by different leadership.
Demands for Leadership and Structural Change
Jana Partners’ list of demands is extensive and targets the very top of the organizational chart. The activist is calling for:
- Immediate External Search for a New CEO: Jana believes the current CEO, Al White, has lost the confidence of the market and failed to execute the company’s strategic goals.
- A New Board Chair: The activist argues that the current board has been too passive and has failed to hold management accountable for the "inflated" inventory and the "hyped" strategic review.
- Revised Compensation Metrics: Implementing new systems to ensure that executive bonuses are tied to genuine operational improvements and stock performance.
- Hiring Performance Consultants: Bringing in outside experts to identify inefficiencies within the CooperVision and CooperSurgical supply chains.
- Engagement with Potential Buyers: Jana is pushing for the board to actively engage with strategic buyers for the Vision business as well, implying that the entire company could be a candidate for a takeover or a merger.
Market Implications and Analyst Outlook
The involvement of Jana Partners typically signals a period of heightened scrutiny and potential volatility for a company’s stock. Analysts in the MedTech space are divided on the likely outcome. Some believe that Cooper’s underlying assets—particularly its dominant position in the contact lens market—are strong enough that a change in leadership could quickly unlock value. Others caution that the "inventory correction" in the vision segment may take several quarters to resolve, regardless of who is in the corner office.
If Cooper Companies resists Jana’s demands, the situation could escalate into a full-scale proxy battle, where shareholders are asked to vote on a competing slate of directors proposed by the activist. Such battles are costly and distracting for management, often leading to a settlement where the activist is granted one or more seats on the board.
Conclusion: A Turning Point for Cooper
Cooper Companies now finds itself at a critical crossroads. The "temporary disconnect" cited by management regarding the value of its surgical segment has evolved into a permanent rift between the company and one of its most vocal institutional investors. As the company prepares for its next series of investor meetings, the pressure to provide a clear, data-driven path to growth has never been higher.
Whether the board will bow to Jana Partners’ demands for a leadership change remains to be seen. However, the activist’s public critique has already succeeded in shifting the narrative around Cooper Companies from one of steady growth to one of strategic urgency. For shareholders, the focus is now squarely on whether the "masterclass in how not to operate" can be transformed into a strategy for sustainable recovery and value creation in a competitive global healthcare market.
